HR Execs on the Move

MnPharm

www.mnpharm.com

 
MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mnpharm.com
  • 1 Imation Way 4Front Technology Campus
    Oakdale, MN USA 55128
  • Phone: 612.455.2515

Executives

Name Title Contact Details

Similar Companies

Three

III International is a company that offers purpose-built, Proactive Wellness products designed to create demonstrable results through maximizing bioavailability and cellular absorption. Their philosophy extends beyond their products and encompasses the...

Windgap Medical

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies.

WCG IRB

WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.